LATISSE™ (bimatoprost ophthalmic solution) 0.03%
is indicated to treat hypotrichosis* of the eyelashes by increasing
their growth including length, thickness, and darkness
Unretouched clinical photos of actual LATISSE™ users. Individual results may vary. In clinical trial, 78% of LATISSE™
patients experienced ≥ 1-grade increase vs 18% for vehicle, and 33% experienced ≥ 2-grade increase vs 1% for vehicle,
on the 4-point Global Eyelash Assessment (GEA) scale† at week 16.1
*Hypotrichosis is another name for having inadequate or not enough eyelashes.
†Patent pending.
Important Safety Information
Contraindications: LATISSE™ is contraindicated in patients with hypersensitivity to bimatoprost or any
other ingredient in this product.
Warnings and Precautions: Bimatoprost ophthalmic solution (LUMIGAN®) lowers intraocular pressure
(IOP) when instilled directly to the eye in patients with elevated IOP. In clinical trials, in patients with or
without elevated IOP, LATISSE™ lowered IOP, however, the magnitude of the reduction was not cause for
clinical concern. In ocular hypertension studies with LUMIGAN®, it has been shown that exposure of the eye
to more than one dose of bimatoprost daily may decrease the intraocular pressure lowering effect. In patients
using LUMIGAN® or other prostaglandin analogs for the treatment of elevated intraocular pressure, the
concomitant use of LATISSE™ may interfere with the desired reduction in IOP. Patients using prostaglandin
analogs including LUMIGAN® for IOP reduction should only
use LATISSE™ after consulting with their physician and should
be monitored for changes to their intraocular pressure.
Please see additional Important Safety Information on the reverse side.
LATISSE™ (bimatoprost ophthalmic solution) 0.03%—the first and only
treatment approved by the FDA indicated to treat hypotrichosis of the eyelashes
by increasing their growth including length, thickness, and darkness
LATISSE™ solution was evaluated for its effect on overall eyelash prominence in a multicenter, double-masked, randomized, vehicle-controlled,
parallel study including 278 adult patients for 4 months of treatment. The primary efficacy endpoint in this study was an increase in overall
eyelash prominence as measured by at least a 1-grade increase on the 4-point Global Eyelash Assessment (GEA) scale*, from baseline to the
end of the treatment period (week 16).2
• LATISSE™ increased eyelash prominence
—Statistically significant differences vs vehicle seen at 8, 12, and 16 weeks2
— 78% of patients experienced an improvement in overall eyelash prominence by week 16
vs 18% for vehicle2
• LATISSE™ improved eyelash growth from baseline as measured by digital-image analysis
assessing eyelash length, fullness/thickness, and darkness2
—Statistically significantly more pronounced in the bimatoprost group at weeks 8, 12,
and 16 2
• The most frequently reported adverse events were:
—Eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye
symptoms, and erythema of the eyelid2
—These events occurred in less than 4% of patients2
LATISSE™ solution is applied once nightly directly to the skin of the upper eyelid margin at the base
of the eyelashes using supplied, FDA-approved sterile applicators2
Important Safety Information
Warnings and Precautions (continued): Increased iris pigmentation has occurred when the same
formulation of bimatoprost ophthalmic solution (LUMIGAN®) was instilled directly onto the eye. Although iridal
pigmentation was not reported in clinical studies with LATISSE™, patients should be advised about the potential
for increased brown iris pigmentation which is likely to be permanent. Bimatoprost has been reported to cause
pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to
increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of
bimatoprost in most patients.
Adverse Reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia,
skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred
in less than 4% of patients.
Note to representative: Please provide full
prescribing information when presenting this material.
How to apply>
Tips for Success>
What to Expect>
FAQs> |
